Clinical Trial: Study of Bone Marrow Samples From Patients With Acute Leukemia

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: Identifying the Genetic Basis of Adult AMKL

Brief Summary:

RATIONALE: Studying the genes expressed in samples of bone marrow from patients with cancer may help doctors identify biomarkers related to cancer.

PURPOSE: This research study is looking at bone marrow samples from patients with acute leukemia.


Detailed Summary:

OBJECTIVES:

  • To perform high throughput sequencing of a set of megakaryocyte specific transcription factors, tyrosine kinases, and Src kinases in DNA isolated from bone marrow specimens of adults with acute megakaryoblastic leukemia (AMKL).
  • To assay the ability of Src kinase inhibitors (SU6656, dasatinib) to induce differentiation of AMKL blasts in these patients.

OUTLINE: DNA from previously collected bone marrow samples are sequenced to analyze genes associated with transcription factors (GATA1, GATA2, SCL, FOG-1, ETS1, ETS2, ERG, FLI-1, GABP, HOXA11, NF-E2, and RUNX1), tyrosine kinases (JAK2, JAK3, and c-MPL), and Src family kinases (LYN, FYN, and HCK) and compared with control DNA. Using bioinformatics, gene alterations are compared to known polymorphisms and subsequent changes in the amino acid sequence of the encoded protein. Subsequent assays assess the effect on proliferation and differentiation and in vitro studies evaluate the consequences of mutations on transcription factor and kinase activity abilities. The effect of SU6656 and dasatinib on cell death and polyploidization is evaluated by flow cytometry and compared with control DNA.


Sponsor: Eastern Cooperative Oncology Group

Current Primary Outcome: Correlation of gene mutations with adult acute megakaryoblastic leukemia (AMKL) [ Time Frame: 1 year ]

Original Primary Outcome:

  • Correlation of gene mutations with adult acute megakaryoblastic leukemia (AMKL)
  • Ability of Src kinase inhibitors (SU6656, dasatinib) to induce differentiation of AMKL blasts


Current Secondary Outcome:

Original Secondary Outcome:

Information By: Eastern Cooperative Oncology Group

Dates:
Date Received: May 9, 2009
Date Started: July 3, 2008
Date Completion:
Last Updated: May 16, 2017
Last Verified: May 2017